Announced

HeartFlow and Glenview Capital-backed Longview Acquisition II terminated a $2.4bn deal.

Synopsis

HeartFlow, a precision heart care firm, and Glenview Capital-backed Longview Acquisition II, a SPAC, terminated a $2.4bn deal. “We believe that our non-invasive, artificial intelligence-enabled, cloud-based enterprise software solution can transform cardiovascular care with risk assessment, diagnosis planning and treatment management. Importantly, we have brought together a talented group of individuals with deep expertise in technology, cardiovascular medicine, and the business of healthcare and a deep commitment to patients to deliver on this vision,” John H. Stevens, HeartFlow MD, President, CEO and Co-Founder.

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Sort

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US